Together these results demonstrate that halofuginone both decreased tumor-induced bone osteolysis and promoted tumor-induced bone formation, and suggest that these effects are partly due to the ability of halofuginone to reduce the expression of RANKL and IL-11 by tumors cells. This evidence concerns the gene IL11 and neoplasm.